Physician profile
Jentry D Riddle
NPI 1003849837
$4,617.82
in general payments reported to CMS, 2019-2025
20 companies · $837 in 2025
The $837 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $656 · 2022: $1,041 · 2023: $1,035 · 2024: $1,049 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,834 · Education: $86.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.11 |
| Education | $86.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,497.62 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $914.38 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Mylan Specialty L.P. | $658.86 | 2021-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $368.78 | 2021-2025 | Dupixent |
| Amgen INC. | $206.74 | 2022-2025 | Tezspire |
| Genzyme Corporation | $191.54 | 2021-2025 | |
| Octapharma USA, INC. | $176.66 | 2021-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Optinose US, INC. | $136.00 | 2021-2023 | |
| Verona Pharma, INC. | $94.19 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $75.61 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Sanofi-Aventis U.S. LLC | $52.99 | 2024 | |
| Kaleo, INC. | $50.46 | 2022 | |
| Pfizer INC. | $42.28 | 2021 | |
| Genentech USA, INC. | $30.63 | 2022 | |
| Incyte Corporation | $28.01 | 2025 | Opzelura |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.71 | 2021 | |
| Phadia US INC. | $20.60 | 2024 | Immunocap |
| Alk-Abello, INC | $18.98 | 2022 | |
| Hikma Pharmaceuticals USA | $16.49 | 2023 | Ryaltris |
| Biocryst US Sales Co., LLC | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jentry Riddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.